about
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Immune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model.Inhibitors of B7-CD28 costimulation in urologic malignancies.Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity.Tumor necrosis factor receptor subfamily 9 (Tnfrsf9) gene is expressed in distinct cell populations in mouse uterus and conceptus during implantation period of pregnancy.HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism4-1BB ligand enhances tumor-specific immunity of poxvirus vaccinesGenetic strategies for brain tumor therapy.The role of checkpoints in the treatment of GBMAnti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancerThe vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentationRecombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL.Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.Advances in immunotherapy for melanoma management.Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.Targeting costimulatory molecules to improve antitumor immunity.Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway.Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy.Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Anti-tumor immunity in a model of acute myeloid leukemia.B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis.Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.Breast Cancer Immunotherapy: An Update.Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival
P2860
Q26765123-4471F535-0657-4796-9B9B-6FE4A906318BQ26765459-E8203F38-0D5A-42ED-A1CD-48A94F42E6F4Q26782566-4DC951C3-37BA-4847-9C11-5196FF0BC628Q27027633-8FFBABD8-3BD5-4A69-972A-D9E781356770Q33603041-AFEB98F5-7E92-42E2-840D-48DC611B4BECQ33685236-68C80E70-33B7-4A3A-9794-26E0B80C805CQ33827752-05969E95-EAA8-46A5-9AF2-AC5D61F22E26Q34039129-282C5C05-4E1E-4C88-A180-BA39B484ECFEQ35013318-DB7A165A-4241-42A2-929C-5D6C41B5A4C5Q35566776-569097A1-C655-4B95-9199-3021624829FAQ35781892-D6CD204F-F030-4C67-A960-EFCB6988ECABQ36247099-AAC7A1C7-24EF-4734-9901-78C576536E0FQ36571197-BFBF3602-5B59-4311-8E95-46D02CD001CFQ36589870-C4078368-C689-4444-AEE6-3B041137B9A5Q36620591-1412BCF1-3AC8-4A48-AC36-31A0A2825A70Q36707828-AE5336E2-88BC-46B2-A26E-5A5EAE297712Q37308070-D75AEC60-F2C9-408D-BE52-03C11420764DQ37375978-73CC7A00-8F79-4821-B446-71C866FB920DQ37729194-5E06C229-DBBD-443D-B7D8-5C8AF7A1F947Q38002404-614A2097-F2FA-4CF7-BB22-387B3C285C63Q38696870-CB21693F-1358-4215-8133-A58E413CE5C8Q38931463-DFEFEBA5-1A64-4795-BC1B-32200623A8D7Q39418029-CBC7F6AD-0D81-4701-8252-8D14B454C0E6Q39641387-DC9475C9-FDE8-4594-8A94-4ADDD894931DQ39886835-883EBD02-39D0-453F-83F9-7D10035BA0F3Q40169401-6AB1F60A-602F-428B-8397-062A8E29D562Q42010165-1A4FAAC3-39DD-4725-8FC0-558F846F0C4EQ42126236-F1F9D3DD-C6EB-4799-B369-8F9135E2158FQ47203993-1EE5D18E-EAE4-4BC0-9EB0-950BCD800A55Q49951608-9202A37D-061F-43EA-BB56-8DF40B2268C6Q51738252-3CD21AF7-04EE-4C5B-8FC6-1500F02D70BDQ52676017-891A6BEE-892D-4A55-9BAB-FB19749D8113Q53344642-8FB28D73-C390-47C0-AFED-8DB5A3FB6159Q55360303-59AE1377-3901-4835-A28E-61472293DCFCQ58861889-9E9F804D-ABFF-4AF0-9B31-D3CCB6A129A7
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@ast
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@en
type
label
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@ast
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@en
prefLabel
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@ast
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
@en
P2860
P356
P1433
P1476
Role of 4-1BB:4-1BB ligand in cancer immunotherapy
@en
P2093
Adam T C Cheuk
Ghulam J Mufti
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700670
P577
2004-03-01T00:00:00Z